Studies have estimated that around 7 to 20 million men suffer from erectile dysfunction. In addition, erectile dysfunction becomes more common and more severe with age.
There is a clear relationship between sexual dysfunction and a poorer sense of wellbeing. A team of researchers wrote, “Sexual dysfunction, and erectile dysfunction in particular, is associated with an enormous burden of illness and poor quality of life.”
PT-141 (also known as bremelanotide) is a peptide that functions as a melanocortin agonist. In simple terms, this means that it is a compound that acts directly on melanocortin receptors in the central nervous system, increasing sexual arousal and performance. It activates the part of the brain that helps you get an erection when desired.
For the significant number of men who suffer from ED and other sexual dysfunction, PT-141 has been shown to be effective at improving performance. A clinical trial recruited men with erectile dysfunction who did not respond adequately to sildenafil (also known as Viagra). The results showed that the drug “resulted in a significant erectile response as compared to the placebo.”
Another study demonstrated that it can work synergistically with sildenafil to enhance erectile response without exacerbating the side effects of either medication.
Remember — sexual health is health. PT-141 ensures optimal sexual health so you can be ready and stay ready.
Disclaimer: This article is for informational purposes only. None of the content in this post should be taken as medical advice. Please discuss symptoms and health goals with your doctor.
References
Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-1144. doi:10.2174/156802607780906681
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200
Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-759. doi:10.1016/j.urology.2004.10.060
Disclaimer: The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.
